BofA upgraded Erasca (ERAS) to Buy from Neutral with an unchanged price target of $5. The firm cites what it views as a favorable risk-reward for the company’s pan-RAS and pan-KRAS assets heading into “a wealth of clinical updates” over the course of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS: